AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,991,834 | -0.6% | 246,039 | -9.3% | 0.00% | 0.0% |
| Q2 2023 | $3,009,849 | 0.0% | 271,402 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $3,009,849 | -1.3% | 271,402 | +8.7% | 0.00% | -50.0% |
| Q4 2022 | $3,048,482 | -99.9% | 249,671 | +13.0% | 0.00% | +100.0% |
| Q3 2022 | $2,306,133,000 | -20.9% | 220,894 | -18.6% | 0.00% | -50.0% |
| Q2 2022 | $2,915,687,000 | +14.4% | 271,479 | +0.9% | 0.00% | +100.0% |
| Q1 2022 | $2,547,675,000 | -21.1% | 269,026 | -3.7% | 0.00% | 0.0% |
| Q4 2021 | $3,228,075,000 | +18.3% | 279,487 | -2.2% | 0.00% | 0.0% |
| Q3 2021 | $2,727,872,000 | -12.9% | 285,641 | -12.1% | 0.00% | 0.0% |
| Q2 2021 | $3,131,429,000 | +0.8% | 324,837 | +3.3% | 0.00% | 0.0% |
| Q1 2021 | $3,107,744,000 | -53.3% | 314,549 | +9.2% | 0.00% | -66.7% |
| Q4 2020 | $6,652,045,000 | -68.7% | 288,092 | -80.9% | 0.00% | -72.7% |
| Q3 2020 | $21,258,761,000 | +385.2% | 1,505,578 | +418.2% | 0.01% | +266.7% |
| Q2 2020 | $4,381,254,000 | +61.0% | 290,534 | -1.4% | 0.00% | +50.0% |
| Q1 2020 | $2,722,058,000 | +1.1% | 294,595 | +6.6% | 0.00% | 0.0% |
| Q4 2019 | $2,691,250,000 | +35.2% | 276,309 | +11.4% | 0.00% | +100.0% |
| Q3 2019 | $1,989,931,000 | -23.3% | 248,121 | +19.3% | 0.00% | -50.0% |
| Q2 2019 | $2,595,665,000 | +21.0% | 207,986 | +31.8% | 0.00% | 0.0% |
| Q1 2019 | $2,145,645,000 | +63.1% | 157,768 | +14.9% | 0.00% | +100.0% |
| Q4 2018 | $1,315,546,000 | -7.4% | 137,322 | +16.9% | 0.00% | 0.0% |
| Q3 2018 | $1,420,708,000 | -23.5% | 117,511 | -1.1% | 0.00% | 0.0% |
| Q2 2018 | $1,856,359,000 | -0.4% | 118,845 | -4.1% | 0.00% | 0.0% |
| Q1 2018 | $1,864,388,000 | +23.5% | 123,962 | +18.1% | 0.00% | 0.0% |
| Q4 2017 | $1,510,158,000 | +56.1% | 104,945 | +63.6% | 0.00% | 0.0% |
| Q3 2017 | $967,412,000 | +89.3% | 64,152 | +26.4% | 0.00% | – |
| Q2 2017 | $511,113,000 | +41.5% | 50,756 | +0.2% | 0.00% | – |
| Q1 2017 | $361,306,000 | +245686.4% | 50,674 | +71.8% | 0.00% | – |
| Q4 2016 | $147,000 | -55.9% | 29,500 | -34.4% | 0.00% | – |
| Q3 2016 | $333,000 | +35.4% | 45,000 | 0.0% | 0.00% | – |
| Q2 2016 | $246,000 | -95.1% | 45,000 | -92.4% | 0.00% | -100.0% |
| Q1 2016 | $5,028,000 | -45.8% | 595,060 | -37.8% | 0.01% | -45.5% |
| Q4 2015 | $9,275,000 | -30.2% | 956,185 | +0.6% | 0.01% | -26.7% |
| Q3 2015 | $13,297,000 | -8.9% | 950,485 | -7.9% | 0.02% | +7.1% |
| Q2 2015 | $14,601,000 | +32.9% | 1,031,900 | +2.2% | 0.01% | +27.3% |
| Q1 2015 | $10,989,000 | +33.1% | 1,010,000 | +1.8% | 0.01% | +37.5% |
| Q4 2014 | $8,257,000 | +40.7% | 992,400 | +0.6% | 0.01% | +33.3% |
| Q3 2014 | $5,867,000 | +28.0% | 986,000 | -28.2% | 0.01% | +20.0% |
| Q2 2014 | $4,585,000 | -9.8% | 1,372,700 | -44.1% | 0.01% | 0.0% |
| Q1 2014 | $5,083,000 | -11.9% | 2,455,400 | 0.0% | 0.01% | -28.6% |
| Q4 2013 | $5,770,000 | +1.3% | 2,455,400 | 0.0% | 0.01% | 0.0% |
| Q3 2013 | $5,697,000 | +96.5% | 2,455,400 | +97.3% | 0.01% | +75.0% |
| Q2 2013 | $2,899,000 | – | 1,244,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |